Lakewood Amedex Biotherapeutics Inc (LABT)

Sep 25, 2026

Is Lakewood-Amedex Biotherapeutics Inc. (LABT) Rewriting the Penny Stocks Playbook? - Kalkine Media

Sep 25, 2026

Sep 25, 2026

Lakewood-Amedex Biotherapeutics Inc. SEC Filing (Sep 25, 2026) - Stock Titan

Sep 25, 2026

Sep 24, 2026

Beyond Antibiotics: Lakewood-Amedex Advances Diabetic Foot Ulcer Trial - AOL.ca

Sep 24, 2026

Sep 24, 2026

Lakewood-Amedex Biotherapeutics (LABT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat

Sep 24, 2026

Sep 24, 2026

Lakewood-Amedex doses first patient in Nu-3 diabetic ulcer trial - Investing.com Canada

Sep 24, 2026

Sep 24, 2026

How Is Lakewood-Amedex (NASDAQ:LABT) Preparing Its Nu-3 Program for Midstage Testing? - Kalkine Media

Sep 24, 2026

Sep 24, 2026

First patient dosed in Phase 2a trial of Nu-3 a... - Pluang

Sep 24, 2026

Sep 24, 2026

The first patient has received a germ-fighting gel being tested for infected diabetic foot ulcers. - Stock Titan

Sep 24, 2026

Sep 22, 2026

Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter Highlighting Transformational Progress & Outlook for Nu-3 - The Columbus Dispatch

Sep 22, 2026

Sep 21, 2026

Lakewood-Amedex CEO outlines progress, Phase 2a trial ahead By Investing.com - Investing.com Nigeria

Sep 21, 2026

Sep 21, 2026

Lakewood-Amedex CEO outlines progress, Phase 2a trial ahead - Investing.com India

Sep 21, 2026

Sep 21, 2026

12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga

Sep 21, 2026

Sep 21, 2026

Lakewood-Amedex Biotherapeutics CEO Issues Letter to Shareholders Highlighting Transformational Progress and Outlook for Nu-3 - PR Newswire

Sep 21, 2026

Sep 20, 2026

IPO Databook: Lakewood-Amedex Biotherapeutics (LABT US)Sep 2026 - Smartkarma

Sep 20, 2026

Sep 19, 2026

Lakewood-Amedex Biotherapeutics Announces IRB Approval and Clinical Site Readiness to Initiate Phase 2a Clinical Trial of Nu-3 for the Treatment of Infected Diabetic Foot Ulcers - TechFinancials

Sep 19, 2026

Sep 18, 2026

Lakewood-Amedex Announces IRB Approval to Initiate Phase 2a Clinical Trial of Nu-3 for Infected Diabetic Foot Ulcers - The National Law Review

Sep 18, 2026

Sep 18, 2026

Lakewood-Amedex (NASDAQ: LABT) faces shareholder stock resale that brings it no cash - Stock Titan

Sep 18, 2026

Sep 18, 2026

LABT Price Today: Lakewood-Amedex Biotherapeutics Inc. Stock Price, Quote & Chart | MEXC - MEXC

Sep 18, 2026

Sep 18, 2026

Lakewood-Amedex Biotherapeutics Announces IRB Approval - openPR.com

Sep 18, 2026

Sep 18, 2026

Lakewood-Amedex receives approval to start phase 2a trial - Investing.com

Sep 18, 2026

Sep 18, 2026

Lakewood-Amedex receives approval to start phase 2a trial By Investing.com - Investing.com Canada

Sep 18, 2026

Sep 18, 2026

A new gel for infected diabetic foot ulcers is ready for a clinical trial - Stock Titan

Sep 18, 2026

Sep 09, 2026

Lakewood-Amedex Biotherapeutics Inc. Common Stock (NASDAQ: LABT) Stock Price, News & Analysis - Kalkine

Sep 09, 2026

Sep 09, 2026

Lakewood-Amedex Biotherapeutics to Present at H.C. Wainwright 28th Annual Global Investment Conference - openPR.com

Sep 09, 2026

Sep 08, 2026

Lakewood-Amedex CEO to present new antimicrobia... - Pluang

Sep 08, 2026

Sep 01, 2026

Biotech Pre-Market Movers: BIAF, LABT, ALMS, PASW Swing Big - RTTNews

Sep 01, 2026

Sep 01, 2026

12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga

Sep 01, 2026

Aug 31, 2026

Trending Stocks Today | SONO Group Soars 81.34% Post-Market - Moomoo

Aug 31, 2026

Aug 31, 2026

12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga

Aug 31, 2026

Aug 29, 2026

Lakewood-Amedex Biotherapeutics Company Profile & Introduction - Moomoo

Aug 29, 2026

Aug 26, 2026

Lakewood-Amedex Biotherapeutics Becomes a B2i Digital Featured Company - markets.businessinsider.com

Aug 26, 2026

Aug 16, 2026

Lakewood-Amedex Biotherapeutics (LABT) Stock Trends and Sentiment 2026 $LABT - MarketBeat

Aug 16, 2026

Aug 14, 2026

Lakewood-Amedex Biotherapeutics (LABT) investor WFI Equity discloses 8.8% ownership stake - Stock Titan

Aug 14, 2026

Aug 14, 2026

Lakewood-Amedex raises $7.5M Series C, lists on Nasdaq and clears $1.5M debt - Dealroom

Aug 14, 2026

Aug 14, 2026

Lakewood-Amedex Raises $7.5M and Lists on NASDAQ, Shedding $1.5M Debt - Minichart

Aug 14, 2026

Aug 14, 2026

LABT: Q2 net loss rose sharply on higher R&D and G&A costs; liquidity improved after Series C financing - TradingView

Aug 14, 2026

Aug 14, 2026

Lakewood-Amedex Biotherapeutics Inc. Q2 2026: Revenue $0 Net loss $(3.90M), EPS $(2.75) — 10-Q Summary - TradingView

Aug 14, 2026

Aug 14, 2026

Lakewood-Amedex (NASDAQ: LABT) raises $7.5M, expands cash yet flags going concern - Stock Titan

Aug 14, 2026

Aug 13, 2026

Upcoming and recent IPOs – IPOs calendar - Yahoo Finance Australia

Aug 13, 2026

Aug 10, 2026

Lakewood-Amedex Biotherapeutics announces annual shareholder meeting - Bitget

Aug 10, 2026

Aug 10, 2026

Lakewood-Amedex (NASDAQ: LABT) seeks 100M share authorization and reverse split power - Stock Titan

Aug 10, 2026

Aug 06, 2026

Lindesfarne LLC reports 8.582% LABT stake in Lakewood-Amedex Biotherapeutics (LABT) filing - Stock Titan

Aug 06, 2026

Aug 06, 2026

Lakewood-Amedex Biotherapeutics (LABT) Earnings Date and Reports 2026 $LABT - MarketBeat

Aug 06, 2026

Jul 30, 2026

Lakewood-Amedex Biotherapeutics (LABT) asks investors to approve major share and reverse split powers - Stock Titan

Jul 30, 2026